¿¬±¸µ¿ÇâÁ¤º¸
Á¦¸ñ Àü¸³¼±¾Ï Á¶±â¼±º°°Ë»çÀÇ ±¹°¡¾Ï°ËÁø»ç¾÷ Çʿ伺
±Û¾´ÀÌ °ü¸®ÀÚ
÷ºÎÆÄÀÏ

  

   [Àü¸³¼±¾Ï Á¶±â¼±º°°Ë»çÀÇ ±¹°¡¾Ï°ËÁø»ç¾÷ Çʿ伺]


 

ÃÖ±Ù Àα¸³ë·ÉÈ­¿Í ´õºÒ¾î Àü¸³¼±¾Ï ȯÀÚ´Â ²ÙÁØÈ÷ Áõ°¡ÇÏ°í ÀÖ´Ù. Àü¸³¼± ¾ÏȯÀÚ Áß 99%°¡ 50´ë ÀÌ»óÀ¸·Î º¸°íµÇ°í ÀÖÀ¸¸ç, ½ÇÁ¦·Î 2016³â Á߾Ӿϵî·Ïº»ºÎ°¡ º¸°Çº¹ÁöºÎ¿Í ÇÔ²² ¹ßÇ¥ÇÑ 'Àü±¹¹Î ¾Ï¹ßº´ Åë°è'¿¡ µû¸£¸é Àü¸³¼±¾ÏÀº ±¹¹ÎÀüü ¾Ï¹ßº´ 7¹ø°, ³²¼º ¾Ï¹ßº´ 5¹ø°·Î, ³ôÀº ¹ßº´·üÀ» º¸ÀÌ°í ÀÖ´Ù. °Ç°­º¸Çè½É»çÆò°¡¿ø(ÀÌÇÏ ½ÉÆò¿ø)ÀÇ Àü¸³¼±¾Ï ÀڷḦ º¸¸é, Àü¸³¼±¾Ï Ä¡·á¸¦ À§ÇØ Áø·á¹ÞÀº ȯÀÚ´Â 2012³â 5¸¸ 413¸í¿¡¼­ 2016³â¿¡´Â 7¸¸ 2620¸íÀ¸·Î 2¸¸ 2207¸íÀÌ ´Ã¾î 5³â »çÀÌ 44%°¡ Áõ°¡Çß´Ù. ¿¬·Éº°·Î´Â 50´ë ÀÌ»óÀÌ 44.5% Áõ°¡ÇßÀ¸¸ç 50´ë ¹Ì¸¸Àº 6%°¡ Áõ°¡ÇßÀ½À» º¸°íÇß´Ù. ÀÌ¿¡ µû¶ó ±¹°¡ ¾Ï Á¶±â°ËÁø»ç¾÷¿¡ Àü¸³¼±¾ÏÀ» Áø´ÜÇÒ ¼ö ÀÖµµ·Ï ÇØ¾ß ÇÑ´Ù´Â ÁÖÀåÀÌ ³ª¿À°í ÀÖ´Ù. ±×·¯³ª Àü¸³¼± ¾Ï¹ßº´·üÀÌ ÃÖ±Ù ¸î³â°£ Á¡Â÷ Áõ°¡ÇÏ°í ÀÖ´Â °ÍÀº »ç½ÇÀÌÁö¸¸ Àü¸³¼± ¾ÏÀ¸·Î ÀÎÇÑ »ç¸ÁÀÚ ¼ö´Â ¿©ÀüÈ÷ ¹Ì±¹°ú À¯·´°ú ºñ±³ÇÏ¿© º¼ ¶§ ³·Àº ¼öÄ¡ÀÌ°í ÀÌ¿¡ ¿ì¸®³ª¶ó ±¹°¡¾Ï°ËÁøÇÁ·Î±×·¥¿¡ Àü¸³¼±°ËÁø Æ÷ÇÔ ¿©ºÎ¿¡ ´ëÇÑ ºñ¿ëÈ¿°ú¿¡ ´ëÇÑ Æò°¡¿¬±¸ÀÇ ÇÊ¿ä°¡ Á¦±âµÇ°í ÀÖ´Ù.  


 

Ç÷û Àü¸³¼±Æ¯ÀÌÇ׿ø¿¡ ÀÇÇÑ Àü¸³¼±¾Ï Á¶±â¼±º°°Ë»çÀÇ ±¹°¡¾Ï°ËÁø»ç¾÷ °æÁ¦¼ºÆò°¡

(Economic evaluation of prostate cancer screening test as a national cancer screening program in South Korea)


 

ÀÓ»óÁú¹®

Àü¸³¼±¾Ï ¼±º°°Ë»ç¸¦ ¿ì¸®³ª¶ó ±¹°¡¾Ï°ËÁøÇÁ·Î±×·¥ (National Cancer Screening Program, NCSP)¿¡ Ãß°¡ÇÏ´Â °ÍÀÌ ºñ¿ë È¿°úÀûÀÎ Ãø¸é¿¡¼­ À¯¿ëÇմϱî?

±Ù°Å±â¹Ý´äº¯

Àü¸³¼± ¾Ï ¹ßº´·üÀÌ ¼­±¸¿Í ºñ±³ÇÏ¿© »ó´ëÀûÀ¸·Î ³·Àº Çѱ¹ÀÇ »óȲ¿¡¼­ Àü¸³¼± ƯÀÌÇ׿ø (Prostate Specific Antigen, PSA) °Ë»ç´Â ºñ¿ë È¿°úÀûÀÎ Ãø¸é¿¡¼­ ±¹°¡¾Ï°ËÁøÇÁ·Î±×·¥¿¡ Æ÷ÇÔÇÏ´Â °ÍÀ» ÃßõÇÏÁö ¾Ê½À´Ï´Ù

¼­ÁöÁ¤º¸

Economic evaluation of prostate cancer screening test as a national cancer screening program in South Korea (2014). Asian Pac J Cancer Prev. 15(8):3383-9.

Áúº´Æ¯¼º

Àü¸³¼±¾Ï(Prostate Cancer)

Ç÷û Àü¸³¼± ƯÀÌÇ׿ø (Prostate Specific Antigen, PSA)¿¡ ÀÇÇÑ Àü¸³¼±¾Ï Á¶±â°ËÁø

¿¬±¸¼³°è

Çѱ¹¿¡¼­ PSA Å×½ºÆ®ÀÇ À¯¿ë¼º Æò°¡¸¦ À§ÇÑ ºñ¿ëÈ¿°úºÐ¼®

µ¥ÀÌÅÍ ÀÚ·á

(Data Materials)

A. 4°¡Áö ÇüÅÂÀÇ Secondary Data µ¥ÀÌÅÍ ¼Ò½º (Çѱ¹ ³²¼º 50~74¼¼ ´ë»ó)

1) ´ëÇк´¿ø °Ç°­°ËÁøÀÚ·á(General health screening data): 2000- 2010³â (Àα¸ÇÐÀûº¯¼ö, ÀÎÅͺä±â·Ï, PSA °Ë»ç°á°ú )

2) Çѱ¹ Áß¾Ó ¾Ï µî·ÏºÎ(Korea Central Cancer Registry): ~2008

3) ±¹¹Î °Ç°­ º¸Çè û±¸¾×(National insurance claims data): Health Insurance Review & Assessment Service (HIRA) claims data (2005-2009)

4) Åë°èû »ç¸Á ¿øÀο¡ °üÇÑ Á¤º¸(Cause of mortality from the National Statistical Office)

B. ³²¼º 160¸í ¸é´ã (40¼¼~ 69¼¼, Face-to Face Interview)

°æÁ¦¼ºÆò°¡ÁöÇ¥

(Economic Evaluation)

-Estimation of transition probabilities

-Estimation of utility

-Cost-effectiveness analysis

-Screening Cost

-Prostate Cancer Costs

-Sensitivity analyses

-Probabilistic sensitivity

Æò°¡ÁöÇ¥

-ºñ¿ëÆíÀͺñÀ² (Incremental cost-effectiveness ratio, ICER)

-9400¸¸¿ø(94,035,213)

»ó¼¼¼³¸í

-ºñ¿ë È¿°ú ºÐ¼®¿¡ µû¸£¸é ICERÀº ¾à 9 õ 4 ¹é¸¸ ¿øÀ¸·Î ³ªÅ¸³²

-¹Î°¨µµ ºÐ¼®Àº Àü¸³¼± ¾Ï ¹ßº´·ü, ½ºÅ©¸®´× ·ü, º´±â ºÐÆ÷, Àü¸³¼± ¾ÏÀÇ À¯¿ë¼º Áö¼ö, Áúº´ Ä¡·á ºñ¿ë µîÀ» »ç¿ëÇÏ¿© ´Ùº¯·® ºÐ¼®À» ½Ç½ÃÇÏ¿´´Ù.

-±× °á°ú´Â ÀÌÀü ¼±Ç࿬±¸¿¡¼­ ¼öÇàÇß´ø ±âº» ºÐ¼®ÀÇ °á°ú¿Í Å©°Ô ´Ù¸£Áö ¾Ê¾Ò´Ù.

-PSA °Ë»ç´Â ºñ¿ëÈ¿°úÃø¸é¿¡¼­ ÀÛÀº À¯À͸¸À» »êÃâÇÏ¿´À¸¸ç, 50-70 ¼¼ ³²¼ºÀÇ Æò±Õ ±â´ë ¼ö¸í°ú ºñ±³Çؼ­ PSA °Ë»ç´Â °æÁ¦ÀûÀ¸·Î À¯¿ë¼ºÀÌ ³ôÀº °Ë»ç¶ó´Â °á·ÐÀº µµÃâµÇÁö ¾Ê¾Ò´Ù.

±Ù°Å¼öÁØ

Moderate

ÀÛ¼ºÀÚ

ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC)

Copyright © 2015 Medical Research Information Center (MedRIC) Editors


 


2018-06-18 ¿ÀÈÄ 3:36:16, Á¶È¸¼ö : 3007